Acta Pediátrica de México

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Acta Pediátrica de México >Year 2013, Issue 3

Arellano-Penagos M, Aranda-Patrón E, López-Sotomayor LL
Pertussis: clinical and bacteriological diagnosis of six cases
Acta Pediatr Mex 2013; 34 (3)

Language: Español
References: 40
Page: 127-131
PDF: 192.12 Kb.

Full text


Pertussis is an endemic disease in our population. Every 3 to 4 years, pertussis has an epidemic pattern even in countries with good health conditions. Antipertussis vaccine first dose is administered at the age of 2 months; a second and third dose are given at 4 and 6 months of age. This vaccine has an 8 to 10 year protective effect, for which reason it is suggested that pregnant women in the third trimester should be vaccinated in order to prevent pertussis in newborns. It should also be administered to older people to avoid turning them into asymptomatic carriers. Clinic manifestations are easily identifiable due to respiratory symptoms, especially to the particular characteristics of the cough. The diagnosis is supported by the presence of leukocytosis (predominantly lymphocytes) and by certain thoracic radiologic findings. The diagnosis is confirmed with a positive culture for Bordetella pertussis or with a polymerase chain reaction (PCR). In a non complicated clinic course macrolides are still the best therapeutic choice. Nonetheless clinic observation is highly recommended in order to avoid complications. Redefinition of vaccine programs against Bordetella pertussis in Mexican population is recommended and also to notify the presence of the disease to the corresponding health authorities.

Key words: Pertussis, Bordetella pertussis, antipertussis vaccine, lymphocytes, leukocytes, polymerase chain reaction (PCR).


  1. Consenso sobre la infección y la prevención de tos ferina. Salud Púb Méx. 2011;53(1):57-65.

  2. Cotter PA, Miller JF. Bordetella. In: Grossman EA Ed. Principles of bacterial pathogenesis. London: Academic Press; 2001. p. 620-774.

  3. Sapian-López LA, Valdespino JL, Salvatierra B, Tapia Conyer R, Gutiérrez G, Macedo J, et al. Seroepidemiology of whooping cough in México. Salud Pública Mex. 1992;34:177-185

  4. Nicholas WMc. Pertussis: review of epidemiololgy diagnosis, management and prevention. Paediatr Resp Rev. 2008;9:201-12.

  5. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europan. Pediatr Infect Dis J. 2005;24:761-5.

  6. InDRE-RNLSP. Lineamientos para la vigilancia por laboratorio de tos ferina y síndrome conqueluchoide. 2012. p. 1-50.

  7. Tomé-Sandoval P, Torres-Arreola LP, Romero Quechol G, Guiscafré-Gallardo H. Bordetella pertussi in adolescents students in Mexico City. Rev Saude Púb. 2008;42:679-83.

  8. Eidltz Markus T, Mimount M, Zeharia A. Pertussis symtoms in adolescents and children versus infants: the influence of vaccinations and age. Clin Pediatr. 2007;46:718-23.

  9. Ward JL, Cherry JD, Chang S, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adult. N Engl J Med. 2005;353:1555-63.

  10. Control de la tos ferina. Guía práctica. Organización Panamericana de la salud. Publicación científica y técnica 604. 2006.

  11. Pérez MA, Rodarte ER, Vázquez Castellanos JL. Panorama clínico-epidemiológico de tos ferina en un hospital de referencia. Pediatr Méx. 2010;12:6-10.

  12. Machin C, Serra A, Olague C, Menchaca A. Protocolo de tratamiento de la tos convulsa grave en la Unidad de cuidados intensivos de niños del centro hospitalario Pereira Rossell. Arch Pediatr Uruguay. 2011;82:173-6.

  13. Paddock C, Sanden G, Cherry D, Langston C, Tati KM, Guarner J, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008;47(3)328-38.

  14. Sandora TJ, Gidengl CA, Lee GM. Pertussis vaccination for health care workers. Clin Microbiol Rev. 2008;21:426-34.

  15. Forsyth KD, Wirsing CH, Caro T, Plotkin S. Prevention of pertussis: recomendation derived from the second Global Pertussis Initiative Roundtable Meeting. Vaccine. 2007;25:2634-42.

  16. Brooks DA, Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med. 2006;19:603-11.

  17. Bamberger ES, Srugol I. What is new in pertussis? Eur J Pediatr. 2008;167:1209-13.

  18. Tan T, Trindale E, Skoiwronsky D. Epidemiology of pertussis. Pediatr infect Dis. 2005;24:510-18.

  19. Wendelboe A, Van Rie A, Salmaso S. Duration of inmunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24:S58-S61.

  20. Healy MC, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clin Infec Dis. 2011;52:157-62.

  21. Peadon E, Cooper C. Whooping cough: are health-care workers putting children at risk? J Paediatr Child Health. 2007;43:398-402.

  22. Rohani P, Drake U. The decline and resurgence of pertussis in the US. Epidemics. 2011;3:183-8.

  23. Casos por entidad federal de enfermedades previsibles hasta la semana epidemiológica 52 del 2011. Fuente SINAVE/DGE/ SALUD 2011.

  24. Escorihuela ER, Barajas SMV. Tos ferina: un problema emergente. Rev Esp Salud Púb. 2002;76:1-4.

  25. Moreno PD, Baquero AF, Gonzalo de LC, Cilleruelo OMJ. Tos ferina. Protocolos Diagnósticos Terapeúticos de la Asociación Española de Pediatría. Infect Pediátr. 2008;82(2):89-96.

  26. Rendl WP. Impact of a pertussis boosters vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J. 2007;26:806-10.

  27. Cherry JD,Grimpel E, Guiso N, Heinninger U, Mertosola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24:S25-34.

  28. Centers for Disease Control and Prevention. Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR 2005;54(RR-14):1-16.

  29. Cortesse MM, Baugman AL, Brown K, Srivastata PA. “New age” in pertussis prevention new oportunities through adult vaccination. Am J prev Med. 2007; 32(3):177-85.

  30. Cherry J. The epidemiology of pertussis: A comparison of the epidemiology of disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115:1422-7.

  31. Gonik B, Puder K, Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol. 2005;13:59-61.

  32. Forsyth K. Pertussis, still a formidable foe. Clin infect Dis. 2007;45(11):1487-91.

  33. Lee GM, Lebaron C, Murphy TV, Lett S, Shauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115(6):1675-84.

  34. World Health Organization. Pertussis vaccine: WHO position paper. Whly Epidemiol Rec. 2005;80(4):31-9.

  35. Galiza EP, Heath PT. Pertussis. Medicine. 2009;37(12):635-7.

  36. Woods N, Mcintye D. Pertussis: review of epidemiology, diagnosis, management and prevention. Pediatr Respir Rev. 2008;9(3):201-9.

  37. Wendenlboe A, Njamkepo E, Bourillon A. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26:293-9.

  38. Wendelboe A, Rie AB, Salmaso S. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infec Dis J. 2005;24:558-78.

  39. Wood N, Mcintyre P, Elliot J. Pertusssis in infancy: A review of strategies for prevention. Expertos Iberoamericana 2007. Avalaible at: www. Siics salud.com/dato/expert.php/85715. Date accesed: 20th December 2007.

  40. Halperin S. The control of pertussis- 2007 and beyond. N Engl Med J. 2007;356:110-13.

>Journals >Acta Pediátrica de México >Year 2013, Issue 3

· Journal Index 
· Links 

Copyright 2019